Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.
[INTRODUCTION] The annual rise in gastrointestinal cancer cases is evident, yet the occurrence of multiple primary malignancies remains comparatively uncommon.
APA
Guo T, Hui Y, et al. (2025). Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.. Immunotherapy, 17(2), 95-101. https://doi.org/10.1080/1750743X.2025.2463309
MLA
Guo T, et al.. "Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report.." Immunotherapy, vol. 17, no. 2, 2025, pp. 95-101.
PMID
39935272
Abstract
[INTRODUCTION] The annual rise in gastrointestinal cancer cases is evident, yet the occurrence of multiple primary malignancies remains comparatively uncommon. In recent years, immunotherapy has swiftly emerged as the leading treatment for several solid tumors, including gastrointestinal cancers. Single treatments might be ineffective, necessitating the need for comprehensive integrative medicine.
[CASE DESCRIPTION] This study reports a case of multiple cancers, including colorectal and gastric cancers. Diverse systemic treatments, like capecitabine, the combination of capecitabine and paclitaxel liposome, as well as capecitabine with toripalimab, were unsuccessful. Nevertheless, prolonged survival was attained through anti-PD-1 immunotherapy complemented by alternative medicine approaches. The patient has exceeded a 35-month survival post-initial diagnosis and 20-month survival since the subsequent diagnosis, markedly surpassing the prognosis often associated with advanced-stage multiple cancers.
[CONCLUSION] In summary, this case underscores the potential effectiveness of a holistic, integrative medical approach in managing advanced multiple malignancies amid drug resistance and disease progression.
[CASE DESCRIPTION] This study reports a case of multiple cancers, including colorectal and gastric cancers. Diverse systemic treatments, like capecitabine, the combination of capecitabine and paclitaxel liposome, as well as capecitabine with toripalimab, were unsuccessful. Nevertheless, prolonged survival was attained through anti-PD-1 immunotherapy complemented by alternative medicine approaches. The patient has exceeded a 35-month survival post-initial diagnosis and 20-month survival since the subsequent diagnosis, markedly surpassing the prognosis often associated with advanced-stage multiple cancers.
[CONCLUSION] In summary, this case underscores the potential effectiveness of a holistic, integrative medical approach in managing advanced multiple malignancies amid drug resistance and disease progression.
MeSH Terms
Humans; Gastrointestinal Neoplasms; Immunotherapy; Programmed Cell Death 1 Receptor; Immune Checkpoint Inhibitors; Male; Middle Aged; Neoplasms, Multiple Primary
같은 제1저자의 인용 많은 논문 (5)
- The role of positive feedback loop between LINC00862 and RBM47 in hepatocellular carcinoma suppression.
- A functionally differentiated DNA tetrahedron-based cascaded cyclic catalytic amplification assay for detecting miR-21 in prostate cancer.
- The Burden of Pancreatic Cancer in Five East Asian Countries From 1990 to 2021 and Its Prediction up to 2036: A Systemic Analysis of the Global Burden of Diseases Study 2021.
- Burden and Future Trends of Gastric Cancer in 5 East Asian Countries From 1990 to 2036: Epidemiological Study Analysis Using the Global Burden of Diseases Study 2021.
- Burden and forecast of colorectal cancer in the selected East Asian countries (1990-2036): a systematic analysis based on the global burden of disease study 2021.